Proposed Experimental Preparation and Administration of Dendritic Cell Vaccine for Treatment of Cancer (Metastatic Castration-Resistant Prostate Cancer)

Abstract

It is suggested that a cause of inefficacy in dendritic cell vaccine is dendritic cell dysfunction. It is proposed that dendritic cell dysfunction is possibly due to the immune-regulatory function of activated platelets in cancer patients. It is suggested that activated platelets in cancer patient suppress dendritic cell activity against a malignant growth. A low platelet count prior to the removal of dendritic cells would possibly yield less dysfunctional dendritic cells. If a low platelet count persist until a complete platelet turnover occurs possibly then the dendritic cells may be less dysfunctional. Furthermore, possibly a temporary immune paralysis may allow collecting dendritic cells least manipulated by the cancerous growth.